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a b s t r a c t
Venlafaxine hydrochloride (VEN) is an antidepressant drug widely used for the treatment of depression.
The purpose of this study was to carry out the preparation and solid state characterization of the pure
polymorphs (Forms 1 and 2) and the polymorphic identiﬁcation and quantiﬁcation of four commercially-
available VEN raw materials. These two polymorphic forms were obtained from different crystallization
methods and characterized by X-ray Powder Diffraction (XRPD), Diffuse Reﬂectance Infrared Fourier
Transform (DRIFT), Raman Spectroscopy (RS), liquid and solid state Nuclear Magnetic Resonance (NMR
and ssNMR) spectroscopies, Differential Scanning Calorimetry (DSC), and Scanning Electron Microscopy
(SEM) techniques. The main differences were observed by DSC and XRPD and the latter was chosen as
the standard technique for the identiﬁcation and quantiﬁcation studies in combination with the Rietveld
method for the commercial raw materials (VEN1–VEN4) acquired from different manufacturers.
Additionally Form 1 and Form 2 can be clearly distinguished from their 13C ssNMR spectra. Through
the analysis, it was possible to conclude that VEN1 and VEN2 were composed only of Form 1, while VEN3
and VEN4 were a mixture of Forms 1 and 2. Additionally, the Rietveld reﬁnement was successfully
applied to quantify the polymorphic ratio for VEN3 and VEN4.
& 2013 Elsevier B.V. All rights reserved.
1. Introduction
Since pharmaceutical solids can have different crystalline struc-
tures, polymorphism is a major concern for the pharmaceutical
industry in the development of new drugs and in relation to the
stability of drugs, since different structures may have different proper-
ties that can inﬂuence the performance of the drug product [1–3].
Polymorphism is deﬁned as the possibility for a substance to have
two or more crystalline forms. The polymorphs differ in terms of
their internal solid-state structure and the arrangement and/or con-
formation of the molecules in the crystalline lattice. Thus, they have
signiﬁcant commercial and industrial implications in various ﬁelds [2].
The different polymorphs can show distinct physical properties,
such as melting point, solubility, dissolution rate and stability (physical
and chemical), which may affect their pharmaceutical processing,
therapeutic efﬁcacy, bioavailability, performance, and quality. These
concerns have led to increased regulatory requirements by the Food
and Drug Administration (FDA) in order to avoid problems related to
polymorphism [3–5].
Understanding the differences in the physical properties of the
polymorphs and their relative stabilities is therefore essential for
the pharmaceutical manufacturers in relation to the selection of a
particular form that has the desirable characteristics for the
administration of the medicines [6,7].
Venlafaxine hydrochloride (VEN), Fig. 1, chemically known as 71-
[2-(dimethylamino)-1-(4-methoxyphenyl)-ethyl] cyclohexanol hydro-
chloride, is an antidepressant drug that acts by simultaneously block-
ing the re-uptake of neuronal norepinephrine and serotonin [8–10].
VEN is a widely prescribed antidepressant drug with sales of US $3.7
billion per annum [11,12].
The recrystallization of VEN can yield crystals with two different
morphologies, that is, blocks (Form 1) and needles (Form 2). The
crystal structure of Form 1 lies in the orthorhombic space group Pca21
according to Vega et al. [13] while Form 2 lies in the monoclinic space
group P21/n, as reported by Sivalakshmidevi et al. [14]. Although the
polymorphs do not show signiﬁcant differences in vivo, Roy et al. [7]
have reported that Form 2 is preferable for the formulation because it
has a larger particle size with better ﬁltration and drying character-
istics. However, Form 2 is under patent and some countries do not
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allow the use of this patented form in pharmaceutical formulations
[7,15,16].
To ensure the ideal polymorphic form for the development of new
formulations and to guarantee the reproducibility and the reliability of
the quality control test procedures applied to the ﬁnal products, the
raw material needs to be well characterized prior to use [5,17].
Different strategies for a systematic study of polymorphism can be
applied and usually involve a combination of different techniques [18].
X-ray powder diffraction (XRPD) is one of the most commonly
used techniques for studying polymorphs. It is the “standard”
procedure for differentiating polymorphs, since each crystal form
produces a diffraction pattern that can be used as its ﬁngerprint
and can thus be employed to screen polymorphs during drug
discovery, formulation development, and manufacturing [19].
Differential scanning calorimetry (DSC), Raman spectroscopy
(RS), diffuse reﬂectance infrared Fourier transform spectroscopy
(DRIFT), solid state nuclear magnetic resonance (ssNMR) and
scanning electron microscopy (SEM) are, among other techniques,
also applied in the characterization of polymorphs [19–22].
The aim of this study was to carry out the preparation and solid
state characterization of the pure VEN polymorphs (Form 1 and
Form 2) through different techniques: XRPD, DRIFT, RS, ssNMR,
DSC and SEM. Additionally, the evaluation of VEN raw materials
purchased from various suppliers was carried out employing XRPD
followed by the Rietveld reﬁnement method in order to identify
the presence and the amount of each polymorphic form.
2. Materials and methods
2.1. Materials
Venlafaxine hydrochloride (CAS 99300-78-4) raw materials were
obtained from different suppliers and were identiﬁed as VEN1–VEN4.
All chemicals used were of pharmaceutical analytical grade.
2.1.1. Preparation of polymorphs
To obtain the monoclinic form (Form 2), approximately 50 mg of
VEN1 was dissolved in 4 mL of methanol:ethyl acetate (1:8, v:v) and
the solution was subjected to low temperature (3–8 1C) until VEN
crystallization was complete [14]. To obtain the orthorhombic form
(Form 1), an amount corresponding to around 50mg of VEN was
dissolved in 2 mL of dichloromethane and allowed to slowly evaporate
under ambient conditions for 5 weeks until all of the solvent had
evaporated. The pure phases 1 and 2 were conﬁrmed by comparing
their XRPD patterns with those calculated from Refs. [13,14].
2.2. Methods
2.2.1. Scanning electron microscopy (SEM)
The morphological characteristics of VEN Forms 1 and 2 and the
four raw materials were observed by scanning electron microscopy
(Phillips XL30). Samples were mounted on metal stubs using double-
side adhesive tape, vacuum-coated with gold (350 Å) in a Polaron
E 5000 sputter coating unit and directly analyzed by SEM (2000 ).
2.2.2. Assay of VEN raw material by HPLC
The assaying of the VEN raw materials was carried out by
a previously validated stability-indicating HPLC method [23].
2.2.3. Powder X-ray diffractometry (PXRD)
The diffraction patterns for VEN were obtained on a Stoe STADI-P
powder diffractometer using Cu Kα1 radiation selected by a Ge (111)
curved monochromator, with a tube voltage of 40 kV and current
of 40 mA, and the signals were detected on a multistrip silicon
detector (Mythen 1 K). The samples were loaded into 0.7-mm boro-
silicate glass capillaries that were kept spinning during the data
collection in the range of 5–501 (2θ) with step sizes of 0.0151 and
60 s of integration time for every 1.051.
2.2.4. Polymorphic quantiﬁcation methodology—
Rietveld reﬁnements
The polymorphic quantiﬁcation of the raw materials VEN3 and
VEN4 was carried out by means of the Rietveld method using the
software program Topas Academic v.4.1 [24] and the published
structural data [13,14] for venlafaxine hydrochloride. The back-
ground was ﬁtted using a 12-term Chebyschev polynomial.
The peak asymmetry was ﬁtted applying the simple axial diver-
gence model of Cheary and Coelho [25,26]. The peak proﬁles were
modeled by the Double–Voigt approach with anisotropic peak
proﬁles adjusted using the 4-term preferred orientation spherical
harmonics of the crystals. Both the peak asymmetry and the peak
proﬁles were kept ﬁxed during the reﬁnement of the VEN samples.
The values were obtained from the reﬁnement of a Si (SRM-640c)
standard reference material distributed by National Institute of
Standards and Technology (NIST, USA). Only the terms describing
the preferred orientation of the crystallites were then reﬁned.
An analytical correction was applied in order to reduce aberrations
affecting data collected with 1D position-sensitive detectors in the
Debye–Scherrer capillary geometry [27].
2.2.5. Differential scanning calorimetry (DSC)
DSC curves were recorded using a Shimadzu DSC-60 cell under
dynamic atmosphere with a 50 mLmin1 nitrogen ﬂow rate. Approxi-
mately 2 mg of each sample of VEN powder were weighted out and
placed in a sealed aluminum pan; an empty aluminum pan was used
as the reference. A heating rate of 2 1Cmin1 was employed over the
temperature range of 30–250 1C.
2.2.6. Diffuse reﬂectance infrared Fourier transform
spectroscopy (DRIFT)
The DRIFT spectra were acquired on a Shimadzu spectrophot-
ometer (Prestige) in the range of 400–4000 cm1 (average of over
32 scans) at a spectral resolution of 4 cm1 in KBr. A background
spectrum was obtained for each experimental condition.
2.2.7. Raman spectroscopy (RS)
Raman spectra were collected in a backscattering geometry
using an Agiltron PeakSeeker 785 PRO Raman system (Woburn,
MA, USA) with a diode laser of 785 nm and 300 mW at the source.
The Raman radiation collected was dispersed with a grating and
focused on a Peltier-cooled charge-coupled device (CCD) detector
obtaining a spectral resolution of 6 cm1. The laser was focused on
the sample by the 20 objective lens of a microscope. All spectra
were recorded in the spectral window of 200–2000 cm1 with the
same acquisition time (15 s). The powders were analyzed on glass
slides at room temperature.
Fig. 1. Chemical structure of venlafaxine hydrochloride.
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2.2.8. Solid-state 13C nuclear magnetic resonance (ssNMR)
High resolution 13C solid state spectra for both Forms 1 and 2 were
recorded using the ramp CP/MAS sequence with proton decoupling
during acquisition. The solid state NMR experiments were performed
at room temperature in a Bruker Avance II spectrometer operating at
300.13 MHz for protons and equipped with a 4 mm MAS probe.
The operating frequency for carbon was 75.46 MHz. Adamantane
was used as an external reference for the 13C spectra and to set the
Harmann–Hahn matching condition in the cross-polarization experi-
ments. The spinning rate was 10 kHz. The values for the number of
transients were 512 and 1024 for Forms 1 and 2, respectively, in order
to obtain an adequate signal to noise ratio. The recycling time was 10 s
for Form 1 and 6 s for Form 2, the contact time during CP was 3 ms
and the acquisition time was 41ms for the two samples. The SPINAL
64 sequence was used for decoupling during acquisitionwith a proton
ﬁeld H1H satisfying ω1H=2π ¼ γH ω1H=2π ¼ 78:2 kHz. Quaternary
carbon spectra were recorded for the two samples. These spectra
were acquired with the non-quaternary suppression (NQS) sequence,
where the 1H and 13C radio-frequency (rf) ﬁelds are removed for 40 μs
after CP and before the acquisition. This delay allows the carbon
magnetization to decay because of the 1H–13C dipolar coupling,
resulting in spectra where CH and CH2 are substantially removed.
This experiment thus allows quaternary carbon signals and methyl
groups to be identiﬁed.
3. Results and discussion
3.1. Solid state characterization of venlafaxine hydrochloride
Forms 1 and 2
In order to obtain a pure sample of each different crystalline forms
of VEN recrystallization experiments were carried out. The pure Forms
1 and 2 were conﬁrmed by comparing their X-ray powder diffraction
(XRPD) patterns with the powder patterns calculated from crystal
structures deposited in the Cambridge Structural Database (CSD)
(Fig. 2) [28,29].
The assay results for the polymorphic forms and commercial
samples of VEN were 499.8%, when evaluated by the stability-
indicating HPLC method [23].
During the crystallization of a substance, external factors can
induce the formation of a particular crystalline habit. The crystal
morphology plays an important role in pharmaceutical processing
and the development of solid dosage forms. Differences in the
crystal habit may strongly inﬂuence the particle orientation and
modify the ﬂowability, packing, compaction, compressibility and
dissolution characteristics [30,31].
The SEM analysis (Fig. 3A) showed two different morphologies
in agreement with the blocks (Form 1) and needles (Form 2)
reported in the literature. The crystal of Form 1 exhibited an
irregular surface with the appearance of overlapped non-ordered
plates. On the other hand, the larger crystals of Form 2 exhibited a
regular acicular habit with a well-deﬁned surface. Fragments of
crystals were deposited on the surface and the smaller acicular
crystals showed a tendency to agglomerate. Roy et al. [7] have
reported that Form 2 has a larger particle size, being preferable for
this formulation; however, the particle sizes of VEN Forms 1 and
2 were not measured in this study.
The fundamental frequency positions in the DRIFT spectra
(Fig. 4A) of both polymorphic forms showed the characteristic
vibrations of VEN, a broad peak related to O–H vibrations at 3450–
3200 cm1, stretching vibrations of CQC at 1513 cm1, followed
by C–O–CH3 stretching at 1246 cm1 and the resonance band at
1183 cm1 for N–C vibrations [32].
The DRIFT spectra of VEN Forms 1 and 2 did not reveal signiﬁcant
differences that could be used to distinguish the two forms. The main
difference was observed only in the large broad peak related to the
O–H vibrations of Form 2. On the basis of the OH vibrations, a
broadening of this band is related to the formation of hydrogen
bonds due to the position of the molecules in the crystalline cell,
conferring higher stability to the structure of Form 2. These results
are in agreement with the DSC data, which revealed a higher
melting point for Form 2.
The Raman spectra of the pure Forms 1 and 2 in the range
of 200–2000 cm1 are presented in Fig. 4B. The features in the
spectra for Forms 1 and 2 are basically the same, although the
former presented slightly sharper peaks with different relative
intensities between 800 and 880 cm1 and a higher baseline.
The baseline increase is attributed to ﬂuorescence effects from
an undeﬁned source, since no degradation was observed. Also,
it could be related to a photo-induced phenomenon. The relative
intensities between 800 and 880 cm1 and the peaks at 1470,
1300, 1250, and 980 cm1 may be used to develop a probe to
distinguish between Forms 1 and 2.
The DSC curves for Forms 1 and 2 of VEN obtained at 2 1C min1
are shown in Fig. 5A and Table 1. The DSC curve for Form 1 revealed a
single sharp endothermic peak even at 208.34 1C (Tonset¼207.77 1C;
ΔHfusion¼106.14 J g1), corresponding to the VEN melting point.
The DSC curve for Form 2 showed a single endothermic event at
214.09 1C (Tonset¼213.61 1C; ΔHfusion¼131.52 J g1) also corre-
sponding to the melting point.
The characterization of VEN polymorphs using DSC has been
previously described in the literature. However, in the related
papers and patents the DSC curves and melting points reported for
Forms 1 and 2 are not always consistent [7,13,14,16].
Roy et al. [16] described that the DSC curves for both forms showed
two endothermic events. The DSC curve for Form 1 exhibited a
Fig. 2. (A) XRPD patterns (1) Form 1 experimental and calculated (WOBMUV) and
(2) Form 2 experimental and calculated (WOBMUV01); and (B) XRPD patterns of
VEN polymorphs: raw material (VEN1–VEN4).
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major endothermic peak at 210–211 1C and a minor peak at
214–215 1C, and the DSC curve for Form 2 displayed an endothermic
peak in the same temperature range observed on the curve for Form 1
(208–209 1C and 215–216 1C) but with the relative size of the peaks
reversed [7,16]. Thus, our results are not in agreement with those
obtained by these authors. In order to conﬁrm the identity and purity
of our polymorphs, the Rietveld method was applied and the results
revealed that the recrystallized Forms 1 and 2 were 100% pure forms.
The two polymorphs of VEN were also studied by ssNMR. The 13C
NMR spectra for VEN Forms 1 and 2 are shown in Fig. 6. The
assignments for the 13C spectra (see carbon numbering in Fig. 1) were
carried out taking into account the quaternary carbon spectra and by
comparing with the solution 13C spectra and simulations obtained
from the commercial software. The 13C ssNMR chemical shifts for both
forms are displayed in Table 2 together with the solution NMR 13C
chemical shifts. The two solid forms can be clearly distinguished based
on their high resolution 13C ssNMR spectra. The 13C spectra for Forms
1 and 2 showed distinct resonances for each carbon in the molecule
and the two polymorphs have a single molecule in the asymmetric
unit. Despite their distinct 13C spectra, the difference in the chemical
shifts for the two cases indicates that the molecular conformations
of the two polymorphs are very similar or that crystal packing effects
have equally large effects, compensating for conformational differ-
ences in the chemical shifts. These ﬁnding are in agreement with the
X-ray results [13,14], verifying the physical purity of the forms.
Polymorphic Forms 1 and 2 were readily distinguishable from
their XRPD patterns (Fig. 2A). The XRPD pattern for Form 1 exhib-
ited two characteristic peaks with diffraction of signiﬁcant inten-
sity at 10.31 and 20.31 (2θ). In addition, peaks at 15.11, 18.311 and
22.751 (2θ) are present only in the case of Form 1. The pattern for
Form 2 showed three Bragg peaks at 2θ (8.41, 12.781 and 16.411),
which are not present in the case of Form 1. These angles were
used for the polymorphic characterization of the commercial
samples.
Fig. 3. (A) SEM photomicrographs of the two polymorphic forms of VEN. (1) Blocks (Form 1) and (2) needles (Form 2) at 200 magniﬁcation; and (B) SEM
photomicrographs of (1) VEN1; (2)—VEN2; (3)—VEN3; and (4)—VEN4; at 2000 magniﬁcation.
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3.2. Solid state characterization of venlafaxine hydrochloride
commercial raw materials
The SEM images of the VEN raw materials (Fig. 3B) conﬁrmed
the differences in the crystalline habit, morphology and particle
size of Forms 1 and 2. The VEN2, VEN3 and VEN4 samples showed
mixtures of particles in the shape of rods and irregular plates (with
the particle size and frequency of aggregates differing between
samples). VEN2 showed large dispersed plates with regular
surfaces. The surfaces of the VEN3 crystals presented rough and
uneven edges and the crystals of VEN4 exhibited irregular surfaces
with ﬁssures and a tendency to form agglomerates. VEN1 con-
tained the smallest particles (rod-like) with well-deﬁned smooth
surfaces, which also showed a tendency to agglomerate.
The DRIFT and Raman spectra of VEN1–VEN4 showed the same
characteristic vibrations for Forms 1 and 2. No signiﬁcance differences
were observed that could distinguish the pure phases or a mixture of
VEN polymorphs in the raw materials.
The DSC curves for VEN1–VEN4 were obtained at 2 1Cmin1
and the results can be observed in Fig. 5B and Table 1. On comparing
the DSC curves for the polymorphic forms VEN1 and VEN2were found
to be associated with Form 1, due to the unique single sharp event
at 209.1 1C, while VEN3 and VEN4 were associated with a mixture
of the two polymorphic forms since two endothermic events can be
observed.
The XRPD patterns of the VEN raw materials (Fig. 2B) conﬁrmed
that VEN1 and VEN2 were composed only of Form 1, whereas VEN3
and VEN4 were a mixture of the two polymorphs. It is worth
highlighting that, although our experiments were performed using
Fig. 4. (A) DRIFT spectra: VEN Forms 1 and 2 and (B) Raman spectra: VEN Forms
1 and 2.
Fig. 5. DSC curves of VEN: (A) Form 1 (dashed lines) and Form 2 (solid lines); and
(B) VEN1–VEN4 obtained with heating rate of 2 1C min1.
Table 1
Data related to the DSC curves for venlafaxine hydrochloride raw materials (VEN1–
VEN4) obtained at a heating rate of 2 1C min1.
Sample Tonset (1C) Tpeak (1C) ΔH (J g1)
Form 1 207.76 208.34 106.14
Form 2 213.61 214.09 131.52
VEN1 208.60 209.40 78.57
VEN2 208.70 209.00 169.85
VEN3 207.15 208.60 110.97
210.60 211.37 3.24
VEN4 206.90 207.95 119.8
211.26 211.96 33.88
Fig. 6. ssNMR spectra of VEN Forms 1 and 2.
Table 2
13C ssNMR chemical shifts for Form 1 and Form 2.
Chemical shift (ppm)
Carbon ssNMR NMR (CDCl3)
Form 1 Form 2
1 135.3 134.3 130.0
2, 6 131.4, 133.3 130.7, 133.8 130.0
3, 5 118.4, 109.4 116.1, 108.8 113.8
4 158.4 158.6 158.6
7 52.0 51.7 52.2
8 74.6 74.7 73.4
9, 13 37.8, 38.6 36.3, 38.4 31.1, 36.4
10, 12 22.0, 24.3 22.1, 22.8 21.0
11 26.6 26.2 25.1
14 60.0 60.0 59.8
15, 16 42.1, 43.9 43.0, 44.0 42.4, 44.8
17 56.3 55.4 55.0
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borosilicate glass capillaries, we observed a slight inﬂuence of pre-
ferred orientation effects. The XRPD technique is a quick tool able to
conﬁrm the presence/absence of the polymorphic forms in the
samples, verifying that XRPD analysis should be included in routine
laboratorial methods.
3.3. Polymorphic quantiﬁcation using the Rietveld method and XRPD
The Rietveld method, originally developed for the reﬁnement
of crystal structures, proved to be very efﬁcient in quantitative
phase analysis, as the Rietveld scale factor of a phase relates to its
relative amount in a multiphase mixture. The method has been
successfully applied to the quantitative application of pharmaceu-
tical solids in recent years [33–35]. Previous studies have demon-
strated that some parameters, such as the type of sample holder,
sample spinning, particle size, powder packing and preferred
orientation effects, are critical in relation to acquiring XRPD
patterns appropriate for use in the Rietveld analysis [33,35,36].
Initially our experiments were performed in a zero background
holder and strong preferential orientation effects were observed.
Therefore, the phase quantiﬁcation procedure was performed using
XRPD patterns collected in 0.7-mm borosilicate glass capillaries in
order to minimize the preferred orientation effect. The ﬁtting of the
Rietveld reﬁnements for samples VEN3 and VEN4 is shown in Fig. 7.
The results revealed 17.5% of Form 1 and 82.5% of Form 2 (70.3)
in VEN3, while VEN4 contained 57.5% of Form 1 and 42.5% of Form 2
(70.8). The goodness of ﬁt indicator and R-factors [37] obtained for
the VEN3 and VEN4 samples were: VEN3—χ2¼1.83, Rwp¼0.0600,
Rp¼0.0422, RBragg_Form_1¼0.0198, and RBragg_Form_2¼0.0237; and
VEN4—χ2¼1.76, Rwp¼0.0542, Rp¼0.0408, RBragg_Form_1¼0.0191, and
RBragg_Form_2¼0.0178.
4. Conclusions
The two pure polymorphs of VEN (Form 1: orthorhombic and Form
2: monoclinic) were obtained from VEN1 through solvent recrystalli-
zation methods. The pure polymorphs and the raw materials (VEN1–
VEN4) were characterized using structural, thermal and spectroscopic
techniques. Forms 1 and 2 were clearly distinguished by XRPD, DSC
and ssNMR. DSC and XRPD analyses showed that VEN1 and VEN2 raw
materials were comprised purely of Form 1, while VEN3 and VEN4
were a mixture of the two forms. The Rietveld reﬁnement procedure
using XRPD data collected by capillary showed that VEN3 has a lower
content of Form 1 and VEN4 has a higher content of Form 1. The XRPD
technique is a powerful tool which can be used to conﬁrm the
presence/absence of the polymorphic forms in the samples and even
quantify them, demonstrating that it should be included in routine
laboratorial methods. Finally, this study showed the diversity in
the solid state properties of VEN available in the market, providing
information on the solid state characterization of the samples in
order to improve the quality control and the reproducibility of the
formulations.
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